Literature DB >> 9203962

Altered interleukin-2 receptor alpha-chain is expressed in human T-cell leukaemia virus type-I-infected T-cell lines and human peripheral blood mononuclear cells of adult T-cell leukaemia patients through an alternative splicing mechanism.

S Horiuchi1, Y Koyanagi, Y Tanaka, M Waki, A Matsumoto, Y W Zhou, M Yamamoto, N Yamamoto.   

Abstract

A polymerase chain reaction (PCR) method was used to detect the interleukin-2 receptor alpha-chain (IL-2R alpha) chain which lacks the conventional transmembrane (TM) domain in mRNA from human T-cell leukaemia virus type-I (HTLV-I)-infected cell lines or peripheral blood mononuclear cells (PBMC) isolated from adult T-cell leukaemia (ATL) patients. Primer pairs encompassing the TM domain were selected to generate a 357-base pair (bp) fragment. A 146-bp PCR product was observed consistently in addition to the target 357-bp PCR product in mRNA from HTLV-I-infected cell lines, such as MT-1, MT-2, MT-4 and in PBMC isolated from ATL patients. However, this 146-bp PCR product was undetectable in HTLV-I-negative cell lines. The product was also detected in PBMC from normal individuals if activated in vitro with phytohaemagglutinin but not without stimulation. DNA sequence analyses revealed that exons from 5 to 7, which define a 211-bp region containing the conventional TM domain, were deleted in the 146-bp PCR product. The C-terminal amino acid sequence starting from Gly174 of the 211-bp-deleted molecule was distinct from that of conventional IL-2R alpha as a result of an altered reading frame. We identified a 45000 MW peptide generated from IL-2R alpha mRNA through this exon skip in cell lysate of MT-1 and MT-2 by Western blot analyses using an antibody raised against the peptides specific to an altered IL-2R alpha. Our results indicate that an altered IL-2R alpha chain is expressed in HTLV-I-infected T lymphocytic cell lines and in ATL patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203962      PMCID: PMC1364031          DOI: 10.1046/j.1365-2567.1997.00236.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

2.  Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering.

Authors:  M Maruyama; H Shibuya; H Harada; M Hatakeyama; M Seiki; T Fujita; J Inoue; M Yoshida; T Taniguchi
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

3.  Natural antibodies to the structural core protein (p24) of the human T-cell leukemia (lymphoma) retrovirus found in sera of leukemia patients in Japan.

Authors:  V S Kalyanaraman; M G Sarngadharan; Y Nakao; Y Ito; T Aoki; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

4.  The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site.

Authors:  J Müllberg; W Oberthür; F Lottspeich; E Mehl; E Dittrich; L Graeve; P C Heinrich; S Rose-John
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

5.  Molecular cloning of cDNA encoding human interleukin-2 receptor.

Authors:  T Nikaido; A Shimizu; N Ishida; H Sabe; K Teshigawara; M Maeda; T Uchiyama; J Yodoi; T Honjo
Journal:  Nature       Date:  1984 Oct 18-24       Impact factor: 49.962

6.  Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism.

Authors:  S Horiuchi; Y Koyanagi; Y Zhou; H Miyamoto; Y Tanaka; M Waki; A Matsumoto; M Yamamoto; N Yamamoto
Journal:  Eur J Immunol       Date:  1994-08       Impact factor: 5.532

7.  Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production.

Authors:  T Hirano; T Taga; K Yasukawa; K Nakajima; N Nakano; F Takatsuki; M Shimizu; A Murashima; S Tsunasawa; F Sakiyama
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

8.  Structure of the human interleukin-2 receptor gene.

Authors:  W J Leonard; J M Depper; M Kanehisa; M Krönke; N J Peffer; P B Svetlik; M Sullivan; W C Greene
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1.

Authors:  J Inoue; M Seiki; T Taniguchi; S Tsuru; M Yoshida
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

View more
  7 in total

1.  Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.

Authors:  Christian M Capitini; Terry J Fry; Crystal L Mackall
Journal:  Am J Immunol       Date:  2009-01-01

2.  High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy.

Authors:  S Horiuchi; W Ampofo; Y Koyanagi; A Yamashita; M Waki; A Matsumoto; M Yamamoto; N Yamamoto
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

3.  The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice.

Authors:  Calliope A Dendrou; Linda S Wicker
Journal:  J Clin Immunol       Date:  2008-09-09       Impact factor: 8.317

4.  Differential use of signal peptides and membrane domains is a common occurrence in the protein output of transcriptional units.

Authors:  Melissa J Davis; Kelly A Hanson; Francis Clark; J Lynn Fink; Fasheng Zhang; Takeya Kasukawa; Chikatoshi Kai; Jun Kawai; Piero Carninci; Yoshihide Hayashizaki; Rohan D Teasdale
Journal:  PLoS Genet       Date:  2006-04-28       Impact factor: 5.917

5.  HTLV-1-infected CD4+ T-cells display alternative exon usages that culminate in adult T-cell leukemia.

Authors:  Morgan Thénoz; Céline Vernin; Hussein Mortada; Maroun Karam; Christiane Pinatel; Antoine Gessain; Thomas R Webb; Didier Auboeuf; Eric Wattel; Franck Mortreux
Journal:  Retrovirology       Date:  2014-12-18       Impact factor: 4.602

6.  Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation.

Authors:  Todd M Brusko; Clive H Wasserfall; Maigan A Hulme; Roniel Cabrera; Desmond Schatz; Mark A Atkinson
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

7.  Clinical and histopathological evaluation of 16 dogs with T-zone lymphoma.

Authors:  Noriyuki Mizutani; Yuko Goto-Koshino; Masashi Takahashi; Kazuyuki Uchida; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2016-04-21       Impact factor: 1.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.